ATE242259T1 - Adenosin a1-rezeptor agonisten - Google Patents

Adenosin a1-rezeptor agonisten

Info

Publication number
ATE242259T1
ATE242259T1 AT98955538T AT98955538T ATE242259T1 AT E242259 T1 ATE242259 T1 AT E242259T1 AT 98955538 T AT98955538 T AT 98955538T AT 98955538 T AT98955538 T AT 98955538T AT E242259 T1 ATE242259 T1 AT E242259T1
Authority
AT
Austria
Prior art keywords
adenosine
receptor agonists
agonists
receptor
Prior art date
Application number
AT98955538T
Other languages
English (en)
Inventor
Philip Charles Box
Brian David Judkins
Andrew Michael Kenneth Pennell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE242259T1 publication Critical patent/ATE242259T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98955538T 1997-11-08 1998-11-06 Adenosin a1-rezeptor agonisten ATE242259T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723566.7A GB9723566D0 (en) 1997-11-08 1997-11-08 Chemical compounds
PCT/EP1998/007022 WO1999024450A2 (en) 1997-11-08 1998-11-06 Adensine a1 receptor agonists

Publications (1)

Publication Number Publication Date
ATE242259T1 true ATE242259T1 (de) 2003-06-15

Family

ID=10821742

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98955538T ATE242259T1 (de) 1997-11-08 1998-11-06 Adenosin a1-rezeptor agonisten

Country Status (24)

Country Link
US (1) US6407076B1 (de)
EP (1) EP1027363B1 (de)
JP (1) JP2001522858A (de)
KR (1) KR20010031883A (de)
CN (1) CN1285842A (de)
AP (1) AP2000001803A0 (de)
AT (1) ATE242259T1 (de)
AU (1) AU1232799A (de)
BR (1) BR9813973A (de)
CA (1) CA2309199A1 (de)
DE (1) DE69815378T2 (de)
EA (1) EA200000393A1 (de)
EE (1) EE200000284A (de)
ES (1) ES2201552T3 (de)
GB (1) GB9723566D0 (de)
HR (1) HRP20000276A2 (de)
HU (1) HUP0004106A2 (de)
IL (1) IL135965A0 (de)
IS (1) IS5478A (de)
NO (1) NO20002360L (de)
PL (1) PL341091A1 (de)
SK (1) SK6712000A3 (de)
TR (1) TR200002157T2 (de)
WO (1) WO1999024450A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6784165B1 (en) 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
GB9930077D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
AU2001280946A1 (en) * 2000-08-01 2002-02-13 University Of Virginia Patent Foundation Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
EP1434782A2 (de) 2001-10-01 2004-07-07 University of Virginia Patent Foundation 2-propynyladenosine-analoge mit a2a-agonistischer aktivität and diese enthaltende gemische
US20090170803A1 (en) * 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
EP1375508A1 (de) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-Substituierte Adenosin Derivate und ihre Verwendung als pharmazeutische Mittel
US7265111B2 (en) 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
US7163928B2 (en) 2003-02-03 2007-01-16 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
JP5046930B2 (ja) * 2004-08-02 2012-10-10 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する修飾５’−リボース基を備えた２−プロピニルアデノシン類似体
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
DE602007013441D1 (de) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
MX2009004715A (es) 2006-10-30 2009-05-20 Novartis Ag Compuestos heterociclicos como agentes antiinflamatorios.
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
EP2391366B1 (de) 2009-01-29 2012-11-28 Novartis AG Substituierte benzimidazole zur behandlung von astrozytomen
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
EP2467141B1 (de) 2009-08-17 2018-10-31 Intellikine, LLC Heterocyclische verbindungen und ihre verwendung
EP2467383A1 (de) 2009-08-20 2012-06-27 Novartis AG Heterocyclische oximverbindungen
MX2012007661A (es) 2010-01-11 2012-08-01 Inotek Pharmaceuticals Corp Combinacion, kit y metodo para reducir la presion intraocular.
CN102811989A (zh) * 2010-02-03 2012-12-05 Meh联合公司 作为具有选择性和生物活性的等排物的多取代氟甲烷
AU2011230580A1 (en) 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (de) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
EP2678016B1 (de) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclische verbindungen und ihre verwendung
EA201391230A1 (ru) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов trk
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
CN104363914A (zh) 2011-11-23 2015-02-18 因特利凯有限责任公司 使用mTOR抑制剂的增强的治疗方案
AU2013211957B2 (en) 2012-01-26 2017-08-10 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of (2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof
EP3964513A1 (de) 2012-04-03 2022-03-09 Novartis AG Kombinationsprodukte mit tyrosinkinaseinhibitoren und deren verwendung
MX2015013234A (es) 2013-03-15 2016-04-15 Inotek Pharmaceuticals Corp Formulaciones oftalmicas.
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
RU2695230C2 (ru) 2014-07-31 2019-07-22 Новартис Аг Сочетанная терапия
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US5652366A (en) * 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
AU2022597A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response

Also Published As

Publication number Publication date
IL135965A0 (en) 2001-05-20
WO1999024450A2 (en) 1999-05-20
TR200002157T2 (tr) 2000-11-21
US6407076B1 (en) 2002-06-18
EA200000393A1 (ru) 2000-12-25
BR9813973A (pt) 2000-09-26
SK6712000A3 (en) 2001-01-18
HRP20000276A2 (en) 2000-12-31
AU1232799A (en) 1999-05-31
EP1027363B1 (de) 2003-06-04
DE69815378T2 (de) 2004-04-29
CN1285842A (zh) 2001-02-28
GB9723566D0 (en) 1998-01-07
DE69815378D1 (de) 2003-07-10
CA2309199A1 (en) 1999-05-20
WO1999024450A3 (en) 1999-08-19
KR20010031883A (ko) 2001-04-16
ES2201552T3 (es) 2004-03-16
NO20002360L (no) 2000-07-05
PL341091A1 (en) 2001-03-26
NO20002360D0 (no) 2000-05-05
IS5478A (is) 2000-05-03
JP2001522858A (ja) 2001-11-20
HUP0004106A2 (hu) 2001-04-28
AP2000001803A0 (en) 2000-06-30
EP1027363A2 (de) 2000-08-16
EE200000284A (et) 2001-08-15

Similar Documents

Publication Publication Date Title
DE69825779D1 (de) Adenosin a1-rezeptor agonisten
ATE242259T1 (de) Adenosin a1-rezeptor agonisten
DE69825780D1 (de) Adenosin a1-rezeptor agonisten
ATA904399A (de) Adenosin a3-rezeptor-modulatoren
DE60007127D1 (de) N-pyrazol a2a rezeptor agonisten
DE60002722D1 (de) C-pyrazol a2a rezeptor agonisten
DK1283839T3 (da) Adenosin A2a-receptorantagonister
IS5706A (is) Adenosín A3 viðtakastillar
PT1090019E (pt) Derivados de adenosina
PT1192170E (pt) Agonistas de receptor a2a de propargilfenileter
DE60234951D1 (de) Adenosin a2a rezeptor antagonisten
NO961887D0 (no) -adrenergiske agonister
DE69835024D1 (de) Allosterische adenosin-rezeptor-modulatore
NO994850D0 (no) Farmakologiske midler
DE69506826D1 (de) 5-HT4 Rezeptoragonisten
ATE231508T1 (de) Azyklische nukleosidderivate
DE60005507D1 (de) Oral aktive a1 adenosin rezeptor agonisten
DK0449175T3 (da) Selektive adenosinreceptormidler
FI955257A (fi) 8-substituoidut-ksantiinit valikoivina adenosiinireseptoriaineina
ID17477A (id) Turunan-turunan pirimidina nukleosida
SE9704276D0 (sv) New thermal analysis system
ID17550A (id) Turunan nukleosida pirimidina
SE9703512D0 (sv) Novel nucleotide receptor
ID17884A (id) Nukleosida-nukleosida pirimidina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties